McManus Peter, Mant Andrea, Mitchell Philip, Britt Helena, Dudley John
Department of Health and Ageing, Canberra, Australian Capital Territory 2605, Australia.
Aust N Z J Psychiatry. 2003 Apr;37(2):184-9. doi: 10.1046/j.1440-1614.2003.01132.x.
To examine the antidepressant prescribing patterns of psychiatrists and general practitioners (GPs) in Australia, focusing specifically on: the prescribed daily dose, the relative proportions (from subsidized dispensing data) of prescriptions written, and how these proportions change over time for a newly listed antidepressant drug (using paroxetine as an example).
Retrospective analyses of subsidized claims data (comprising nearly 90% of the community supply of antidepressants) and prescriber surveys.
General practitioners prescribe 86% of subsidized antidepressants in Australia. Almost three-quarters of the antidepressant prescriptions prescribed in primary care management are also initiated by a GP. Psychiatrists prescribed higher doses than general practitioners for all the antidepressants examined. For paroxetine, a higher than average proportion of scripts were written by psychiatrists when the drug was initially available and it only reached the GP/psychiatrist split seen with an established drug in the same therapeutic class (fluoxetine) four years after marketing. The most prominent type of depression that GPs believed they were treating was 'chronic mild depression', which contrasts with the subsidized indication for all newer antidepressant classes of 'major depressive disorders'.
General practitioners are the major providers of treatment for depression in Australia. When writing prescriptions for tricyclic antidepressants GPs use doses lower than those recommended for major depression, however, most management in primary care is not for conditions regarded by the GP as major depression. A significant number of prescriptions for the newer antidepressants may not accord with the Pharmaceutical Benefits Scheme (PBS) restrictions for use.
研究澳大利亚精神科医生和全科医生(GP)的抗抑郁药物处方模式,特别关注:规定的每日剂量、开具处方的相对比例(来自补贴配药数据),以及一种新上市抗抑郁药物的这些比例随时间的变化情况(以帕罗西汀为例)。
对补贴报销数据(占社区抗抑郁药物供应量近90%)进行回顾性分析,并开展开处方者调查。
在澳大利亚,全科医生开具了86%的补贴抗抑郁药物处方。在初级保健管理中开具的抗抑郁药物处方,近四分之三也是由全科医生首次开出的。在所研究的所有抗抑郁药物中,精神科医生开具的剂量高于全科医生。对于帕罗西汀,该药物最初上市时,精神科医生开具的处方比例高于平均水平,且在上市四年后才达到与同一治疗类别中已上市药物(氟西汀)相同的全科医生/精神科医生处方比例。全科医生认为他们治疗的最主要抑郁症类型是“慢性轻度抑郁症”,这与所有新型抗抑郁药物补贴适应症的“重度抑郁症”形成对比。
在澳大利亚,全科医生是抑郁症治疗的主要提供者。开具三环类抗抑郁药物处方时,全科医生使用的剂量低于重度抑郁症推荐剂量,然而,初级保健中的大多数治疗并非针对全科医生认为的重度抑郁症。大量新型抗抑郁药物的处方可能不符合药品福利计划(PBS)的使用限制。